Stockscreener 앱 받기
40.78
0.87%
0.3375
전일 마감가:
$40.44
열려 있는:
$40.32
하루 거래량:
861.09K
Relative Volume:
0.41
시가총액:
$6.13B
수익:
$3.24B
순이익/손실:
$304.90M
주가수익비율:
19.60
EPS:
2.08
순현금흐름:
$156.70M
1주 성능:
+2.85%
1개월 성능:
+11.88%
6개월 성능:
-33.50%
1년 성능:
-41.77%
1일 변동 폭
$40.28
$41.00
1주일 범위
$38.60
$41.00
52주 변동 폭
$34.10
$79.78
Bruker Corp Stock (BRKR) Company Profile
명칭
Bruker Corp
전화
978663-3660
주소
40 MANNING RD, BILLERICA, MA
BRKR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BRKR
Bruker Corp
|
40.78 | 6.13B | 3.24B | 304.90M | 156.70M | 2.08 |
|
ABT
Abbott Laboratories
|
132.33 | 224.65B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.61 | 151.13B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
382.98 | 139.34B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.51 | 108.80B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
75.47 | 44.25B | 5.54B | 4.18B | 259.90M | 7.00 |
Bruker Corp Stock (BRKR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-19 | 개시 | Guggenheim | Buy |
| 2024-12-10 | 개시 | UBS | Neutral |
| 2024-12-05 | 업그레이드 | Goldman | Sell → Neutral |
| 2024-10-15 | 개시 | Barclays | Overweight |
| 2024-09-30 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-08-28 | 개시 | Wells Fargo | Overweight |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-02-14 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-12-19 | 개시 | Wells Fargo | Equal Weight |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2022-10-21 | 개시 | UBS | Buy |
| 2022-08-22 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-10-15 | 재개 | Cowen | Market Perform |
| 2021-06-15 | 업그레이드 | Cleveland Research | Neutral → Buy |
| 2021-02-05 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-12-02 | 개시 | Goldman | Sell |
| 2020-11-16 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2020-05-01 | 다운그레이드 | Cleveland Research | Buy → Neutral |
| 2020-04-02 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2020-04-01 | 다운그레이드 | Needham | Strong Buy → Hold |
| 2020-03-26 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-01-08 | 개시 | Wells Fargo | Overweight |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-11-15 | 개시 | Stifel | Hold |
| 2019-09-26 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-07-15 | 업그레이드 | Goldman | Sell → Neutral |
| 2019-06-24 | 재확인 | Needham | Strong Buy |
| 2019-06-21 | 재확인 | BofA/Merrill | Neutral |
| 2019-05-30 | 개시 | Wolfe Research | Peer Perform |
| 2019-05-06 | 재확인 | Needham | Strong Buy |
| 2019-05-03 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-03 | 업그레이드 | UBS | Sell → Neutral |
| 2019-04-12 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2019-02-12 | 재확인 | BTIG Research | Buy |
| 2019-01-03 | 개시 | Needham | Strong Buy |
모두보기
Bruker Corp 주식(BRKR)의 최신 뉴스
Nanorobots Market Size to Exceed USD 38,660 Million by 2034, Rising Demand for Targeted Drug Delivery is Driving Market Growth. - GlobeNewswire Inc.
Bruker announces majority acquisition of RECIPE, a leading provider of mass spectrometry-based diagnostic assay kits for therapeutic drug monitoring - Select Science
Press Release Distribution & PR Platform - ACCESS Newswire
Bruker to launch Beacon Discovery at AACR 2025, expanding access to live single-cell functional analysis - Select Science
Bruker Spatial Biology Pushes Boundaries in Spatial Biology and Multiomics at AACR 2025 – Company Announcement - Financial Times
Bruker to Launch Beacon Discovery™ at AACR 2025, Expanding Access to Live Single-Cell Functional Analysis - Financial Times
Bruker Corporation (BRKR): Among Mid-Cap Stocks Insiders Were Buying in Q1 2025 - Insider Monkey
A Glimpse Into The Expert Outlook On Bruker Through 6 Analysts - Benzinga
Bruker to invest in German company RECIPE - Yahoo Finance
Bruker Introduces nVista 2P Miniature Microscope - Quantisnow
BRUKER CORP : Results of Operations and Financial Condition, Regulation FD Disclosure (form 8-K) - marketscreener.com
Bruker (BRKR) Acquires Majority Stake in RECIPE Chemicals + Instruments | BRKR Stock News - GuruFocus
Bruker Announces Majority Acquisition of RECIPE, a Leading Provider of Mass Spectrometry-based Diagnostic Assay Kits for Therapeutic Drug Monitoring - Yahoo Finance
Bruker (BRKR) Acquires Majority Stake in RECIPE Chemicals + Inst - GuruFocus
Bruker Stock May Benefit Following Its Investment in Ridom GmbH - Yahoo Finance
Bruker (BRKR) Projects Revenue Growth Amid Mixed Segment Performance | BRKR Stock News - GuruFocus
Form DEF 14A BRUKER CORP For: May 29 - StreetInsider
Why Is Life Science Focused Bruker Stock Trading Higher On Friday?Bruker (NASDAQ:BRKR) - Benzinga
Bruker Debuts Fourier 80 Multinuclear Benchtop FT-NMR: Stock to Gain? - Yahoo Finance
Bruker Crushes Q1 Revenue Estimates: Double-Digit Growth Signals Strong Performance - Stock Titan
Bruker Complements Fast, Cost-effective IR Biotyper® Hospital Hygiene Testing and HAI Tracing with NGS Reflex Testing – Company AnnouncementFT.com - Financial Times
Bruker Launches FoodScreener Module for Comprehensive NMR-based Profiling of Honey - Global Food Industry News
Is Now An Opportune Moment To Examine Bruker Corporation (NASDAQ:BRKR)? - Yahoo Finance
Bruker Announces Groundbreaking 1.3 GHz NMR System, Stock Up - Nasdaq
Bruker unveils world’s first 1.3 GHz NMR spectrometer - Investing.com
Bruker Announces First-of-a-kind 1.3 GHz High-Resolution NMR System - Financial Times
Bruker Introduces Innovative Fourier 80 Multinuclear Benchtop FT-NMR – Company Announcement - Financial Times
Revolutionary Multi-Nuclear NMR Technology Transforms Pharma and Battery Research - Stock Titan
Bruker Introduces Breakthrough d-DNP Polarizer: Stock to Gain? - MSN
Should You Think About Buying Bruker Corporation (NASDAQ:BRKR) Now? - simplywall.st
Bruker installs novel MRI polarizer at UCSF for cancer research - Investing.com
Bruker Announces Introduction of Revolutionary d-DNP Polarizer for MRI Research and for Dynamic Nuclear Polarization Liquids NMR – Company AnnouncementFT.com - Financial Times
Game-Changing MRI Breakthrough: New Technology Delivers 10,000x Better Imaging for Cancer Research - Stock Titan
Bruker stock hits 52-week low at $42.68 amid market challenges By Investing.com - Investing.com South Africa
Bruker stock hits 52-week low at $42.68 amid market challenges - Investing.com
Is Bruker Corporation (BRKR) an Oversold Value Stock to Buy According to Hedge Funds? - Insider Monkey
Bruker : Introduces eWARP, a Pioneering New EBSD Detector for Advanced Materials Characterization in Scanning Electron Microscopes - MarketScreener
Bruker stock hits 52-week low at $44 amid market challenges By Investing.com - Investing.com South Africa
Bruker stock hits 52-week low at $44 amid market challenges - Investing.com
Victory Capital Management Inc. Decreases Stock Holdings in Bruker Co. (NASDAQ:BRKR)Insurance News - InsuranceNewsNet
Bruker Corporation (BRKR): Among Michael Burry’s Top Holdings - Insider Monkey
Based On Its ROE, Is Bruker Corporation (NASDAQ:BRKR) A High Quality Stock? - Yahoo Finance
Michael Burry’s Top Holdings Were Gaining While NVDA Was Crashing - Insider Monkey
Bruker Co. (NASDAQ:BRKR) Shares Sold by Charles Schwab Investment Management Inc. - Defense World
FY2027 Earnings Estimate for Bruker Issued By Zacks Research - Defense World
BioSpin's Innovations to Support Bruker Shares, Macro Issues to Ail - Yahoo Finance
Bruker Co. (NASDAQ:BRKR) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Bruker at Leerink Conference: Navigating Challenges and Opportunities By Investing.com - Investing.com South Africa
Bruker at Leerink Conference: Navigating Challenges and Opportunities - Investing.com
Bruker at Barclays Healthcare Conference: Navigating Headwinds and Tailwinds By Investing.com - Investing.com South Africa
Bruker stock hits 52-week low at $45.13 amid market challenges - Investing.com Australia
Bruker Corp (BRKR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Bruker Corp 주식 (BRKR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Bures Thomas | Chief Accounting Officer |
Mar 10 '25 |
Buy |
47.40 |
500 |
23,698 |
3,472 |
| LAUKIEN FRANK H | PRESIDENT & CEO |
Feb 18 '25 |
Buy |
50.92 |
20,000 |
1,018,330 |
38,459,563 |
| PACKER RICHARD A | Director |
Dec 02 '24 |
Option Exercise |
19.12 |
10,000 |
191,200 |
84,254 |
| PACKER RICHARD A | Director |
Dec 02 '24 |
Sale |
57.82 |
3,350 |
193,683 |
80,904 |
10.06%
0.20%
자본화:
|
볼륨(24시간):